Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GFER | P55789 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2648606 | 0.85 | ADRA2C (0.53) | ADRA2CMEN1KMT2ATSHRMAPT | |
| SCHEMBL16824829 | 0.85 | GFER (0.53) | ADRA2CMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL17152957 | 0.84 | ALDH1A1 (0.42) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL2661949 | 0.83 | ADRA2C (0.50) | ADRA2CMEN1KMT2ATSHRMAPT | |
| SCHEMBL5783473 | 0.82 | ENPP2 (0.51) | MAPTALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL27482946 | 0.82 | SMN1; SMN2 (0.63) | ADRA2CMEN1KMT2ATSHRMAPT | |
| SCHEMBL18412523 | 0.81 | CA12 (0.50) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL18412526 | 0.81 | SIGMAR1 (0.53) | TSHRMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL30198151 | 0.80 | GPR119 (0.60) | ADRA2CMAPTALDH1A1GPR119LMNA | |
| SCHEMBL265132 | 0.80 | GPR119 (0.60) | ADRA2CMAPTALDH1A1GPR119LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936613-B2 | Benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S (DK) | 2005-08-30 | — | — | US | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| US-6649609-B2 | For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children | NEUROSEARCH A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | ADRA2C 40/4885MEN1 4632/4885KMT2A 1116/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | ADRA2C 39/4885MEN1 4691/4885KMT2A 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.